PALISADE BIO, INC.
PALINext catalyst
PALI-2108
Ulcerative Colitis (UC)
Get an email about PALI's next catalysts
Track PALISADE BIO (PALI) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
No other upcoming event in our data.
1 upcoming, 2 past
PALI-2108 Phase 2 Est. Readout (ASCENTRA-UC)
Estimated primary completion for PALI-2108 trial (NCT07845487) in Ulcerative Colitis (UC). Topline data typically follows completion by weeks to months.
SourceMarket Overview
Stock performance and key metrics
Frequently asked questions
What is in PALISADE BIO, INC.'s drug pipeline?β
CatalystAlert tracks 2 drug candidates in PALISADE BIO, INC.'s (PALI) pipeline across Phase 2. Its lead program is PALI-2108 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is PALISADE BIO, INC.'s next FDA catalyst?β
PALISADE BIO, INC.'s (PALI) next tracked catalyst is a Phase 2 readout expected October 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track PALI biotech catalysts?β
Add PALI to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow PALISADE BIO, INC.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page β sourced from ClinicalTrials.gov, FDA and SEC filings.
